Literature DB >> 21287350

Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.

Francesca Palandri1, Nicola Polverelli, Lucia Catani, Emanuela Ottaviani, Michele Baccarani, Nicola Vianelli.   

Abstract

Established risk factors for thrombosis in essential thrombocythemia (ET) include age (≥ 60 years) and previous vascular events. Recently, also leukocytosis has been proposed in risk stratification of ET patients. We report a retrospective study on 532 ET patients followed for a median of 7.6 years. Sixty-four patients (12%) developed 95 thrombotic events during follow-up. Together with the high-risk condition, a white blood cell (WBC) value above 11 × 10⁹/L, corresponding to the fourth percentile value, significantly correlated with a higher thrombotic risk (p = 0.033) by Cox proportional hazards. Moreover, the cumulative risk of thrombosis was significantly higher in high-risk patients with WBC >11 × 10⁹/L. JAK2 V617F mutation did not correlate with thrombosis. Overall, 123 (23%) patients died. Three independent parameters were noted as prognostic factors for survival in multivariate analysis: age > 60 years, leukocytosis >11 × 10⁹/L, and hemoglobin level below normal values. Based on these parameters, three groups of risk were defined, with significantly different survivals. Baseline leukocytosis correlated with a higher thrombotic risk in high-risk patients and identified a cohort of patients with worse survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21287350     DOI: 10.1007/s00277-010-1154-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  17 in total

1.  Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Authors:  Alessandra Carobbio; Alberto Ferrari; Arianna Masciulli; Arianna Ghirardi; Giovanni Barosi; Tiziano Barbui
Journal:  Blood Adv       Date:  2019-06-11

Review 2.  Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Authors:  L Falchi; H M Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

3.  Ph- myeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide.

Authors:  Milan Košťál; Jiří Schwarz; Petra Ovesná; Miroslav Penka; Petr Dulíček
Journal:  J Thromb Thrombolysis       Date:  2021-01       Impact factor: 2.300

4.  Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.

Authors:  F Palandri; R Latagliata; N Polverelli; A Tieghi; M Crugnola; B Martino; M Perricone; M Breccia; E Ottaviani; N Testoni; F Merli; F Aversa; G Alimena; M Cavo; G Martinelli; L Catani; M Baccarani; N Vianelli
Journal:  Leukemia       Date:  2015-03-24       Impact factor: 11.528

Review 5.  Cerebral thrombosis and myeloproliferative neoplasms.

Authors:  Andrea Artoni; Paolo Bucciarelli; Ida Martinelli
Journal:  Curr Neurol Neurosci Rep       Date:  2014-11       Impact factor: 5.081

Review 6.  Are MPNs vascular diseases?

Authors:  Guido Finazzi; Valerio De Stefano; Tiziano Barbui
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

7.  Persistent neutrophilia is a marker for an increased risk of venous thrombosis.

Authors:  Margarita Kushnir; Hillel W Cohen; Henny H Billett
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

8.  The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia.

Authors:  Danijela Lekovic; Mirjana Gotic; Natasa Milic; Predrag Miljic; Mirjana Mitrovic; Vladan Cokic; Ivo Elezovic
Journal:  Med Oncol       Date:  2014-09-16       Impact factor: 3.064

Review 9.  Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas.

Authors:  Shubhabrata Das; Anasua Deb; Tanmoy Pal
Journal:  Med Princ Pract       Date:  2021-04-13       Impact factor: 1.927

10.  Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts.

Authors:  Juan Zhou; Yuanxin Ye; Shugen Zeng; Yi Zhou; Zhigang Mao; Xingbo Song; Binwu Ying; Xiaojun Lu; Hong Jiang; Lanlan Wang
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.